← Leaderboards
William T Dauer
Ut Southwestern Medical Center
$16,076,801
Attributed
$18,403,788
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,251,818 · 20
By mechanism
R01$12,398,512 · 7
P50$10,647,550 · 4
P01$1,776,017 · 1
K02$750,175 · 1
R56$509,222 · 1
P41$170,342 · 6
Top collaborators
- Dhananjay Yellajoshyula6 shared
- Henry N Ginsberg4 shared
- Howard J Worman4 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Philipp E Scherer$40,932,820
- Lauren Nicole Miterko$144,774
- Bhavya Ramesh Shah$1,631,895
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsPathogenesisFunctional DisorderMutationBaseMotorLinkBrainDystoniaGenesCellsParkinson DiseaseTorsinaProteinsMolecularComplexPreventBehavioralGeneticInsightIn VivoSignal TransductionMediatingCorpus Striatum Structure
Grant awards (66)
Cell Type Specific Genetic Manipulation to Dissect Cholinergic Interneuron Function and Plasticity in a Symptomatic Model of DYT1 Dystonia$454,382
R01 · FY2025 · NS · contact PI
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$426,237
R01 · FY2025 · NS
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$82,296
R01 · FY2025 · NS
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$46,840
R01 · FY2025 · NS
Cell Type Specific Genetic Manipulation to Dissect Cholinergic Interneuron Function and Plasticity in a Symptomatic Model of DYT1 Dystonia$489,721
R01 · FY2024 · NS · contact PI
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$413,450
R01 · FY2024 · NS
Cell Type Specific Genetic Manipulation to Dissect Cholinergic Interneuron Function and Plasticity in a Symptomatic Model of DYT1 Dystonia$504,867
R01 · FY2023 · NS · contact PI
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$426,237
R01 · FY2023 · NS
Development of an Animal Model of Task Specific Dystonia$409,272
R01 · FY2023 · NS · contact PI
Nuclear Envelope, Lipoprotein Metabolism, and Hepatic Steatosis$524,391
R01 · FY2022 · DK
Cell Type Specific Genetic Manipulation to Dissect Cholinergic Interneuron Function and Plasticity in a Symptomatic Model of DYT1 Dystonia$502,161
R01 · FY2022 · NS · contact PI
Role of DYT6 Dystonia Protein THAP1 in Oligodendroglial Mediated ECM Homeostasis During CNS Development$441,487
R01 · FY2022 · NS
Development of an Animal Model of Task Specific Dystonia$408,383
R01 · FY2022 · NS · contact PI
Nuclear Envelope, Lipoprotein Metabolism, and Hepatic Steatosis$524,393
R01 · FY2021 · DK
Cell Type Specific Genetic Manipulation to Dissect Cholinergic Interneuron Function and Plasticity in a Symptomatic Model of DYT1 Dystonia$516,285
R01 · FY2021 · NS · contact PI
Development of an Animal Model of Task Specific Dystonia$408,395
R01 · FY2021 · NS · contact PI
Nuclear Envelope, Lipoprotein Metabolism, and Hepatic Steatosis$524,393
R01 · FY2020 · DK
Development of an Animal Model of Task Specific Dystonia$429,791
R01 · FY2020 · NS · contact PI
Nuclear Envelope, Lipoprotein Metabolism, and Hepatic Steatosis$539,893
R01 · FY2019 · DK
Development of an Animal Model of Task Specific Dystonia$466,664
R56 · FY2019 · NS · contact PI
Administrative Core$81,115
P50 · FY2019 · NS · contact PI
Development of an Animal Model of Task Specific Dystonia$42,558
R56 · FY2019 · NS · contact PI
Administrative Core$196,104
P50 · FY2018 · NS · contact PI
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease$1,793,405
P50 · FY2017 · NS · contact PI
TorsinA function and dystonia-related dysfunction in developing and mature CNS$386,676
R01 · FY2017 · NS · contact PI
Administrative Core$178,842
P50 · FY2017 · NS · contact PI
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease$1,840,995
P50 · FY2016 · NS · contact PI
TorsinA function and dystonia-related dysfunction in developing and mature CNS$386,676
R01 · FY2016 · NS · contact PI
Administrative Core$179,370
P50 · FY2016 · NS · contact PI
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease$1,500
P50 · FY2016 · NS · contact PI
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease$1,891,185
P50 · FY2015 · NS · contact PI
TorsinA function and dystonia-related dysfunction in developing and mature CNS$386,676
R01 · FY2015 · NS · contact PI
Administrative Core$196,105
P50 · FY2015 · NS · contact PI
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease$2,320,945
P50 · FY2014 · NS · contact PI
TorsinA function and dystonia-related dysfunction in developing and mature CNS$380,905
R01 · FY2014 · NS · contact PI
Administrative Core$225,254
P50 · FY2014 · NS · contact PI
TorsinA function and dystonia-related dysfunction in developing and mature CNS$384,752
R01 · FY2013 · NS · contact PI
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY$340,297
P50 · FY2013 · NS · contact PI
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY$376,132
P50 · FY2012 · NS · contact PI
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY$352,634
P50 · FY2011 · NS · contact PI
LRRK2 IN PARKINSON'S DISEASE$37,024
P41 · FY2011 · RR · contact PI
TORSINA FUNCTION IN THE NUCLEAR MEMBRANE$37,024
P41 · FY2011 · RR · contact PI
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY$342,360
P50 · FY2010 · NS · contact PI
The Mechanism of LRRK2-Mediated Neurodegneration in Parkinson's Disease$305,910
R01 · FY2010 · NS · contact PI
TORSIN AND THE NUCLEAR ENVELOPE$23,907
P41 · FY2010 · RR · contact PI
RNAi for DYT1 Dystonia$354,999
P01 · FY2009 · NS · contact PI
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY$331,307
P50 · FY2009 · NS · contact PI
The Mechanism of LRRK2-Mediated Neurodegneration in Parkinson's Disease$260,159
R01 · FY2009 · NS · contact PI
The Mechanism of LRRK2-Mediated Neurodegneration in Parkinson's Disease$50,674
R01 · FY2009 · NS · contact PI
TORSIN AND THE NUCLEAR ENVELOPE$31,168
P41 · FY2009 · RR · contact PI
RNAi for DYT1 Dystonia$369,130
P01 · FY2008 · NS · contact PI
The Mechanism of LRRK2-Mediated Neurodegneration in Parkinson's Disease$322,000
R01 · FY2008 · NS · contact PI
The mechanism of MPTP resistance in synuclein null mice.$120,035
K02 · FY2008 · NS · contact PI
TORSIN AND THE NUCLEAR ENVELOPE$19,512
P41 · FY2008 · RR · contact PI
RNAi for DYT1 Dystonia$370,613
P01 · FY2007 · NS · contact PI
Molecular and Cellular Mechanisms of Primary Dystonia$353,020
R01 · FY2007 · NS · contact PI
The mechanism of MPTP resistance in synuclein null mice.$120,035
K02 · FY2007 · NS · contact PI
TORSIN AND THE NUCLEAR ENVELOPE$21,707
P41 · FY2007 · RR · contact PI
Molecular and Cellular Mechanisms of Primary Dystonia$363,564
R01 · FY2006 · NS · contact PI
RNAI for DYT1 Dystonia$332,948
P01 · FY2006 · NS · contact PI
The mechanism of MPTP resistance in synuclein null mice.$170,035
K02 · FY2006 · NS · contact PI
Molecular and Cellular Mechanisms of Primary Dystonia$372,313
R01 · FY2005 · NS
RNAI for DYT1 Dystonia$348,327
P01 · FY2005 · NS
The mechanism of MPTP resistance in synuclein null mice.$170,035
K02 · FY2005 · NS
Molecular and Cellular Mechanisms of Primary Dystonia$372,313
R01 · FY2004 · NS
The mechanism of MPTP resistance in synuclein null mice.$170,035
K02 · FY2004 · NS